Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has reached a key milestone in its ongoing imaging collaboration with Massachusetts General Hospital, reporting that patient enrollment in the pilot study has reached the halfway mark and preliminary imaging data are encouraging. The study evaluates a novel positron emission tomography (PET) imaging tracer designed to differentiate between reversible and permanent nerve damage in multiple sclerosis (MS) lesions.
Multiple sclerosis is one of the most common neurological diseases affecting young adults worldwide. Approximately 2.9 million people are living with the disease globally, and nearly one million of those individuals are in the United States. Most people are diagnosed between the ages of 20 and 40, meaning MS strikes during some of the most productive years of a person's life. The ability to distinguish between reversible and irreversible nerve damage could significantly impact treatment decisions and drug development.
Quantum BioPharma is a biopharmaceutical company focused on neurodegenerative and metabolic disorders. The imaging study is part of the development program for Lucid-MS, the company's MS drug candidate. The early imaging data showing a meaningful signal in MS lesions is a promising sign that the PET tracer may effectively track disease progression and response to therapy.
For more information on Quantum BioPharma, visit the company's newsroom at https://nnw.fm/QNTM.
This milestone underscores the potential of advanced imaging techniques to improve understanding of MS pathology and accelerate the development of targeted therapies. As enrollment continues, further data will help validate the approach and its utility in clinical trials.
